% | $
Quotes you view appear here for quick access.

Chelsea Therapeutics Internation Message Board

onemodolar 4 posts  |  Last Activity: Jul 11, 2015 4:19 PM Member since: Dec 28, 2011
SortNewest  |  Oldest  |  Highest Rated Expand all messages
  • onemodolar by onemodolar Jul 11, 2015 4:19 PM Flag

    If MRNS says they will go for this, easy 50% pop from here, IMO.

  • onemodolar onemodolar Jul 11, 2015 4:09 PM Flag

    Shorts covered!
    From 508k to 84k in matter of last 2 weeks.
    Partnership or Oral formulation coming into clinic or Good progress with current trial.
    Recent 5 insider purchases although total amount is about 20k shares.
    Something may be on the way - secondary offering will be later when pps is higher.

    Sentiment: Hold

  • Reply to

    SAGE effect

    by andre_y_mb Jun 9, 2015 1:26 PM
    onemodolar onemodolar Jun 9, 2015 2:35 PM Flag

    Thanks Andre,
    Even Ohad did not expect this :-)
    Did MRNS know about this? Do they have ANY data about anti-depress effect of ganaloxone?
    SAGE does not have oral formulation yet,
    MRNS does and it's already P2/P3 stage, HUGE advantage!
    This can be a game changer.
    Post partum depression can make MRNS BO target.
    I decided to stay put to see how this unfolds.

  • onemodolar by onemodolar May 15, 2015 2:47 PM Flag

    Selling pressure is waning down.
    I think there is huge potential buy interests - short covering and for those who tendered and got paid $50/sh ( may be about 14 or 15 million shares) These people know well about what FMI does. Excluding shares locked by
    Roche, current actual float can be as low as only 5 million shares. In view of this, I believe sellers can not keep the price down for too long. Slow progress in reimbursement has triggered this sell off and it has been similar like this after each ER last year. More massive this time. Actually FMI is less vulnerable than ever before because of fresh $250 million infusion from Roche.
    I even have much more FMI shares now than prior to tender.